Deutsche Bank Provides Color on Covidien, Buy

Deutsche Bank provided color on Covidien

after Bloomberg published an article about the company's plans for its pharmaceuticals business. In a research report published today, Deutsche Bank states, "Last evening a Bloomberg article stated that Covidien had been working with an investment bank regarding options for the pharmaceuticals business... It stated COV had been in talks with another healthcare company, but discussions recently broke down though other potential buyers are still looking at the business." At the moment, Deutsche Bank has a Buy rating and a price target of $61 placed on the company's stock. On Tuesday, Covidien closed the day at $54.31.